Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study

The Lancet Rheumatology

Volumn 2, Issue 2, 2020, Pages e84-e98

  Pawar, Ajinkya ^a   Desai, Rishi J ^a   Gautam, Nileesa ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; JANUS KINASE INHIBITOR; METHOTREXATE; OPIATE; SALAZOSULFAPYRIDINE; STEROID; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HAZARD RATIO; HERPES ZOSTER; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; META ANALYSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; VIRUS INFECTION;

EID: 85078250900     PISSN: None     EISSN: 26659913     Source Type: Journal    
DOI: 10.1016/S2665-9913(19)30137-7     Document Type: Article

References (30)

1. Fleischmann, R, Pangan, AL, Song, IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial. Arthritis Rheumatol 71 (2019), 1788–1800.
2. Taylor, PC, Keystone, EC, van der Heijde, D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376 (2017), 652–662.
3. Desai, RJ, Solomon, DH, Jin, Y, Liu, J, Kim, SC, Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm 23 (2017), 809–814.
4. Au, K, Reed, G, Curtis, JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70 (2011), 785–791.
5. Strand, V, Ahadieh, S, French, J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther, 17, 2015, 362.
6. Singh, JA, Wells, GA, Christensen, R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev, 2011 CD008794.
7. Chen, SK, Liao, KP, Liu, J, Kim, SC, Risk of hospitalized infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. Arthritis Care Res 72 (2020), 9–17.
8. Curtis, JR, Xie, F, Chen, L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 70 (2011), 1401–1406.
9. Yun, H, Xie, F, Delzell, E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 68 (2016), 56–66.
10. van Dartel, SA, Fransen, J, Kievit, W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 72 (2013), 895–900.
11. Favalli, EG, Desiati, F, Atzeni, F, et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 8 (2009), 266–273.
12. Grijalva, CG, Chen, L, Delzell, E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306 (2011), 2331–2339.
13. Harrold, LR, Litman, HJ, Saunders, KC, et al. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther, 20, 2018, 2.
14. Machado, MAA, Moura, CS, Guerra, SF, Curtis, JR, Abrahamowicz, M, Bernatsky, S, Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther, 20, 2018, 60.
15. Curtis, JR, Xie, F, Yun, H, Bernatsky, S, Winthrop, KL, Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1843–1847.
16. Lee, EB, Fleischmann, R, Hall, S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
17. Burmester, GR, Kremer, JM, Van den Bosch, F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391 (2018), 2503–2512.
18. Bechman, K, Subesinghe, S, Norton, S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58 (2019), 1755–1766.
19. Kim, SY, Servi, A, Polinski, JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther, 13, 2011, R32.
20. Yawn, BP, Saddier, P, Wollan, PC, St Sauver, JL, Kurland, MJ, Sy, LS, A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82 (2007), 1341–1349.
21. Donahue, JG, Choo, PW, Manson, JE, Platt, R, The incidence of herpes zoster. Arch Intern Med 155 (1995), 1605–1609.
22. Gagne, JJ, Glynn, RJ, Avorn, J, Levin, R, Schneeweiss, S, A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 64 (2011), 749–759.
23. Austin, PC, Stuart, EA, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
24. Nguyen, TL, Collins, GS, Spence, J, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol, 17, 2017, 78.
25. Ripollone, JE, Huybrechts, KF, Rothman, KJ, Ferguson, RE, Franklin, JM, Implications of the Propensity Score Matching Paradox in Pharmacoepidemiology. Am J Epidemiol 187 (2018), 1951–1961.
26. Bechman, K, Subesinghe, S, Norton, S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology 58 (2019), 1755–1766.
27. Pawar, A, Desai, RJ, Solomon, DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis 78 (2019), 456–464.
28. Rutherford, AI, Subesinghe, S, Hyrich, KL, Galloway, JB, Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 77 (2018), 905–910.
29. Schneeweiss, S, Setoguchi, S, Weinblatt, ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 56 (2007), 1754–1764.
30. Curtis, JR, Yang, S, Patkar, NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 66 (2014), 990–997.